Professor Ruth Chambers (August 2001 JRSM, pp. 375± 377) says that many people use the word`involve' as an umbrella term. My interpretation is cover-up.
There is a saying,`The doctor who treats himself is dealing with two stupid people'. In clinical practice we take a history, conduct an examination and then request special investigations when indicated. This enables us to advise patients about the diagnosis and treatment. Such advice is based on current knowledgeÐoften limitedÐwhich needs to be expressed in words that the individual patient can understand, not easy when we are steeped in medical terms. The advice we give is occasionally wrong; only the insightless are invariably right. The patient has to decide whether to take the adviceÐin total, in part or not at all. Some years ago a patient with cluster headache, having been given the correct diagnosis by three consultants told me that they had not convinced him. I had not previously considered this aspect of a consultation and remain puzzled by the means with which we convince patients. Any ideas?
J N Blau
St John & Elizabeth Hospital, 60 Grove End Road, London NW8 9NH, UK Professor Chambers says that a survey of 250 people might cost £2000. I calculate 2 second class stamps=38p, 2 envelopes 2p, survey document A4 photocopy6265p=10p, total 50p6250=£125. That leaves a healthy £1875 for management and overheads. In a nutshell, it indicates that though possibly worth the effort it is not worth the cost.
P L Jenkins
St Joseph's Hospital, Newport NP9 6EZ, Wales, UK
Anticoagulants for deep venous thrombosis
In their case report of super®cial thrombophlebitis followed by pulmonary embolism (April 2001 JRSM, pp. 186±187) Dr Kesteven and Mr Robinson raise the question whether anticoagulants should be used to treat super®cial venous thrombosis. This might be a good subject for a clinical trial; however, even the use of anticoagulants in venous thromboembolismÐi.e. deep venous thrombosis (DVT) and pulmonary embolism (PE)Ðis open to doubt. No randomized placebo-controlled trial has ever been published supporting the ef®cacy or safety of anticoagulants in DVT. To justify anticoagulant treatment of DVT patients, textbooks and review articles generally lump DVT with PE and cite a placebo-controlled randomized trial of patients with PE by Barritt and Jordan 1 . The authors of this old and small study (n=35) used clinical signs and symptoms without lung scans or angiograms to diagnose PE. We now know that clinical suspicion of PE is con®rmed by angiograms in only about 25% of cases 2 . Also, assignment of fatal PE as the cause of death was questionable in at least three of the ®ve placebo group patients with severe underlying co-morbidity. In short, Barritt and Jordan's 
